Search

Displaying results 5101 - 5110 of 10000 in total
  1. Drug

    PMI-001

    go.drugbank.com/drugs/DB05730
    Experimental

    PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc. … It is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis

  2. Drug

    Human Menstrual Blood-derived Stem Cells

    go.drugbank.com/drugs/DB15738
    Investigational

    Because this is a non-invasive way to obtain stem cells, it is simple and easy to obtain the stem cells with an absence of ethical issues that may come from obtaining stem cells of the embryonic kind. … MenSCs are special compared to older methods of adult stem cell extraction such as bone marrow stem cell extraction because MenSC extraction is a non-invasive method.

  3. Drug

    FP0011

    go.drugbank.com/drugs/DB05090
    Experimental

    FP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease). … It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties.

  4. Drug

    Anecortave acetate

    go.drugbank.com/drugs/DB05288
    Investigational

    Anecortave acetate (Retaane) is an analog of cortisol acetate; among the modifications to the steroid are the removal of the 11ß hydroxyl OH group and an addition of a 21-acetate group. … As a result of these modifications, anecortave acetate lacks the typical antiinflammatory and immunosuppressive properties of glucocorticoids.Alcon Inc. is developing and marketing Retaane.

  5. Drug

    BI-765063

    go.drugbank.com/drugs/DB17482
    Investigational

    BI-765063 is a humanized IgG4 monoclonal antibody antagonist of signal regulatory protein α (SIRPα).

  6. Drug

    Drinabant

    go.drugbank.com/drugs/DB05750
    Investigational

    It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease. … AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant.

  7. Drug

    BOS172722

    go.drugbank.com/drugs/DB15498
    Investigational

    BOS172722 is a novel and selective Monopolar spindle 1 (Mps1) kinase inhibitor identified as a potential anticancer agent. … The key role of Mps1 in the growth of cancer cells renders it an appealing target for cancer treatment, as its inhibition could lead to favorable effects.

  8. Drug

    Scutellaria lateriflora

    go.drugbank.com/drugs/DB14339
    Approved

    Scutellaria lateriflora is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  9. Drug

    CIGB 300

    go.drugbank.com/drugs/DB16464
    Investigational

    CIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma

  10. Drug

    GT 389-255

    go.drugbank.com/drugs/DB05894
    Experimental

    MAD) Phase I trials. … Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and